Antirheumatic Agents

"Antirheumatic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Drugs that are used to treat RHEUMATOID ARTHRITIS.

Descriptor ID	D018501
MeSH Number(s)	D27.505.954.329
Concept/Terms	Antirheumatic Agents Antirheumatic Agents Anti-Rheumatic Drugs Anti Rheumatic Drugs Antirheumatic Drugs Anti-Rheumatic Agents Anti Rheumatic Agents Antirheumatic Drugs, Disease-Modifying Antirheumatic Drugs, Disease-Modifying Antirheumatic Drugs, Disease Modifying DMARD Disease-Modifying, Antirheumatic Second-Line Drugs Disease Modifying, Antirheumatic Second Line Drugs Antirheumatic Disease-Modifying Second-Line Drugs Antirheumatic Disease Modifying Second Line Drugs Disease-Modifying Antirheumatic Drugs Disease Modifying Antirheumatic Drugs Anti-Rheumatic Agents, Non-Steroidal Anti-Rheumatic Agents, Non-Steroidal Anti Rheumatic Agents, Non Steroidal Non-Steroidal Anti-Rheumatic Agents

Below are MeSH descriptors whose meaning is more general than "Antirheumatic Agents".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Therapeutic Uses [D27.505.954]
Antirheumatic Agents [D27.505.954.329]

Below are MeSH descriptors whose meaning is more specific than "Antirheumatic Agents".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Antirheumatic Agents" by people in this website by year, and whether "Antirheumatic Agents" was a major or minor topic of these publications.

Bar chart showing 60 publications over 20 distinct years, with a maximum of 6 publications in 2014 and 2015

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2002	2	0	2
2003	2	1	3
2005	0	2	2
2006	0	1	1
2007	2	2	4
2008	1	1	2
2009	3	0	3
2010	1	1	2
2011	5	0	5
2012	3	0	3
2013	2	2	4
2014	3	3	6
2015	3	3	6
2016	2	2	4
2017	1	0	1
2019	0	2	2
2020	2	2	4
2021	2	0	2
2023	2	0	2
2024	1	1	2

Below are the most recent publications written about "Antirheumatic Agents" by people in Profiles.

Barlas N, Barlas S, Adalier E, Basnyat S. Pigmented villonodular synovitis and rheumatoid arthritis: diagnostic challenges and therapeutic considerations in a case of knee pain. BMJ Case Rep. 2024 May 31; 17(5).

View in: PubMed
Saito K, Gabbeta A, Mulvihill E, Al-Jaberi L, Beukelman T, Lewis JD, Rose CD, Strom BL, Horton DB. Validation of new medication use algorithms as proxies for worsening disease activity in patients with juvenile idiopathic arthritis. Pharmacoepidemiol Drug Saf. 2024 May; 33(5):e5803.

View in: PubMed
Dal?n J, Svedbom A, Hernlund E, Olofsson T, Black CM. Identifying Predictors of First-Line Subcutaneous TNF-Inhibitor Persistence in Patients with Inflammatory Arthritis: A Decision Tree Analysis by Indication. Adv Ther. 2023 10; 40(10):4657-4674.

View in: PubMed
Di Martino A, Ursini F, Bordini B, Ancarani C, Ciaffi J, Brunello M, D'Agostino C, Faldini C. Perioperative treatment with TNF inhibitors does not affect survival of total hip arthroplasty in inflammatory arthritis: A registry-based cohort study. Semin Arthritis Rheum. 2023 Jun; 60:152201.

View in: PubMed
Dal?n J, Chitkara A, Svedbom A, Olofsson T, Puenpatom A, Black CM, Qureshi ZP. Health-Care and Societal Costs Associated with Non-Persistence with Subcutaneous TNF-a Inhibitors in the Treatment of Inflammatory Arthritis (IA): A Retrospective Observational Study. Adv Ther. 2022 06; 39(6):2468-2486.

View in: PubMed
Dal?n J, Puenpatom A, Luttropp K, Svedbom A, Black CM. Treatment Persistence in Patients Cycling on Subcutaneous Tumor Necrosis Factor-Alpha Inhibitors in Inflammatory Arthritis: A Retrospective Study. Adv Ther. 2022 01; 39(1):244-255.

View in: PubMed
Dove ML, Jaggi P, Kelleman M, Abuali M, Ang JY, Ballan W, Basu SK, Campbell MJ, Chikkabyrappa SM, Choueiter NF, Clouser KN, Corwin D, Edwards A, Gertz SJ, Ghassemzadeh R, Jarrah RJ, Katz SE, Knutson SM, Kuebler JD, Lighter J, Mikesell C, Mongkolrattanothai K, Morton T, Nakra NA, Olivero R, Osborne CM, Panesar LE, Parsons S, Patel RM, Schuette J, Thacker D, Tremoulet AH, Vidwan NK, Oster ME. Multisystem Inflammatory Syndrome in Children: Survey of Protocols for Early Hospital Evaluation and Management. J Pediatr. 2021 02; 229:33-40.

View in: PubMed
Deaner JD, Srivastava SK, Hajj-Ali RA, Lowder CY, Venkat AG, Baynes K, Sharma S. Recurrence Rates of Inflammation after Switching from the Originator Infliximab to Biosimilar Infliximab-abda for Noninfectious Uveitis. Am J Ophthalmol. 2021 05; 225:172-177.

View in: PubMed
Dal?n J, Luttropp K, Svedbom A, Black CM, Kachroo S. Healthcare-Related Costs Associated with Switching Subcutaneous Tumor Necrosis Factor-a Inhibitor in the Treatment of Inflammatory Arthritis: a Retrospective Study. Adv Ther. 2020 09; 37(9):3746-3760.

View in: PubMed
Harrold LR, Shan Y, Rebello S, Kramer N, Connolly SE, Alemao E, Kelly S, Kremer JM, Rosenstein ED. Disease activity and patient-reported outcomes in patients with rheumatoid arthritis and Sj?gren's syndrome enrolled in a large observational US registry. Rheumatol Int. 2020 Aug; 40(8):1239-1248.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement